Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.55 |
| ▸ | PPARG | P37231 | 11/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197265 | 0.86 | PPARG (0.56) | FFAR1PPARGCYP3A4RXRAPPARA | |
| SCHEMBL9312385 | 0.83 | PPARG (0.59) | FFAR1PPARGCYP3A4RXRAPPARA | |
| SCHEMBL19559777 | 0.82 | FFAR1 (0.61) | FFAR1PPARGCYP3A4RXRAPPARA | |
| SCHEMBL8932687 | 0.81 | IDO1 (0.54) | PPARGCYP3A4MEN1ALDH1A1TP53 | |
| SCHEMBL12515224 | 0.81 | FFAR1 (0.69) | FFAR1PPARGCYP3A4RXRAPPARA | |
| SCHEMBL6931578 | 0.80 | FFAR1 (0.59) | FFAR1PPARGCYP3A4RXRAPPARA | |
| SCHEMBL6511107 | 0.80 | PPARG (0.46) | FFAR1PPARGPPARAMAPT | |
| SCHEMBL1072226 | 0.79 | FFAR1 (0.77) | FFAR1PPARGCYP3A4PPARAHRH3 | |
| SCHEMBL21504844 | 0.78 | FFAR1 (0.59) | FFAR1PPARGCYP3A4RXRAPPARA | |
| SCHEMBL9570670 | 0.77 | FFAR1 (0.71) | FFAR1PPARGCYP3A4RXRAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942898-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | claimed |
| EP-1942898-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-1931350-A2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-06-18 | — | — | EP | claimed |
| WO-2007033265-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033266-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033350-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2016100301-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015134752-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE AND/OR INJURY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20130122008-A1 | Anti-IL 1- ß Antibody Combination Therapy | NOVARTIS AG | 2013-05-16 | — | — | US | disclosed |
| EP-2531501-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097079-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | WO | disclosed |
| EP-2346498-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | Metabolex Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2003076393-A1 | SALTS OF NATEGLINIDE | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122008-A1 | Anti-IL 1- ß Antibody Combination Therapy | G6PC1, FBP1, GCKR | FFAR1 152/4885PPARG 100/4885CYP3A4 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.